Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing int… Read more
Market Cap & Net Worth: Cleo Diagnostics Ltd (COV)
Cleo Diagnostics Ltd (AU:COV) has a market capitalization of $41.95 Million (AU$67.75 Million) as of March 19, 2026. Listed on the AU stock exchange, this Australia-based company holds position #24762 globally and #519 in its home market, demonstrating a -1.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cleo Diagnostics Ltd's stock price AU$0.50 by its total outstanding shares 136862085 (136.86 Million).
Cleo Diagnostics Ltd Market Cap History: 2023 to 2026
Cleo Diagnostics Ltd's market capitalization history from 2023 to 2026. Data shows growth from $14.83 Million to $41.95 Million (39.61% CAGR).
Cleo Diagnostics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cleo Diagnostics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
43.27x
Cleo Diagnostics Ltd's market cap is 43.27 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $14.83 Million | $110.08K | -$1.73 Million | 134.72x | N/A |
| 2024 | $30.08 Million | $600.15K | -$3.76 Million | 50.13x | N/A |
| 2025 | $51.27 Million | $1.18 Million | -$4.00 Million | 43.27x | N/A |
Competitor Companies of COV by Market Capitalization
Companies near Cleo Diagnostics Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Cleo Diagnostics Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Cleo Diagnostics Ltd Historical Marketcap From 2023 to 2026
Between 2023 and today, Cleo Diagnostics Ltd's market cap moved from $14.83 Million to $ 41.95 Million, with a yearly change of 39.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$41.95 Million | -18.18% |
| 2025 | AU$51.27 Million | +70.42% |
| 2024 | AU$30.08 Million | +102.86% |
| 2023 | AU$14.83 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Cleo Diagnostics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.95 Million USD |
| MoneyControl | $41.95 Million USD |
| MarketWatch | $41.95 Million USD |
| marketcap.company | $41.95 Million USD |
| Reuters | $41.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.